Drug intelligence / Profile preview

candesartan + rosuvastatin

Development stage
Unknown
Lead developer
Alvogen
Modality
Small Molecules
Administration
Oral
01

Overview

**candesartan + rosuvastatin** is a fixed-dose oral combination drug used for the concurrent treatment of hypertension (high blood pressure) and hypercholesterolemia (high cholesterol). Candesartan is a selective angiotensin II type 1 receptor antagonist that blocks the action of angiotensin II, thereby reducing blood vessel constriction and lowering blood pressure. Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) which lowers cholesterol by inhibiting the enzyme involved in cholesterol biosynthesis, reducing LDL cholesterol and total cholesterol levels. The combination improves medication adherence and provides synergistic cardiovascular protection by addressing two major risk factors for cardiovascular disease: elevated blood pressure and dyslipidemia[1][2][6].

Other names
candesartan + rosuvastatin
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on candesartan + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on candesartan + rosuvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call